Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency.
Yutaka TakahashiBeverly M K BillerHidenori FukuokaKen K Y HoMichael Højby RasmussenNavid NedjatianClaus SværkeKevin C J YuenGudmundur JohannssonPublished in: Pituitary (2022)
Somapacitan, compared with daily GH, did not adversely affect glucose metabolism up to 86 weeks in a large cohort of treatment-naïve or previously treated patients with AGHD. Trial registrations (date of registration): NCT02229851 (2 September 2014), NCT02382939 (3 March 2015), NCT03075644 (7 March 2017).